Menu
Search
|

Menu

Close
X

ENDRA Life Sciences Inc NDRA.OQ (NASDAQ Stock Exchange Capital Market)

1.61 USD
-0.12 (-6.94%)
As of 4:00 PM EDT
Previous Close 1.73
Open 1.70
Volume 7,578
3m Avg Volume 23,382
Today’s High 1.70
Today’s Low 1.59
52 Week High 5.75
52 Week Low 0.90
Shares Outstanding (mil) 7.42
Market Capitalization (mil) 12.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
1
EPS (USD)
FY19
-0.370
FY18
-2.272
FY17
-1.595
FY16
-1.845
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
3.20
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-293.13
12.69
Return on Equity (TTM)
vs sector
-293.13
17.13

EXECUTIVE LEADERSHIP

Francois Michelon
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $262,152.00
Bonus: --
David Wells
Chief Financial Officer, Since 2017
Salary: $96,000.00
Bonus: --
Michael Thornton
Chief Technology Officer, Since 2007
Salary: $218,056.00
Bonus: --
Renaud Maloberti
Chief Commercial Officer, Since 2019
Salary: --
Bonus: --
Anthony DiGiandomenico
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3600 Green Ct Ste 350
ANN ARBOR   MI   48105-2440

Phone: +1734.3350468

ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing Thermo Acoustic Enhanced Ultrasound (TAEUS) for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue.

SPONSORED STORIES